Artificial Coma/Medically Induced Coma Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 3.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Artificial Coma/Medically Induced Coma Market Analysis
The Artificial Coma/Medically Induced Coma Market is expected to register a CAGR of 3% during the forecast period.
Factors such as an increase in cases of brain injury and diseases and a rise in surgical procedures, coupled with the increased adoption of artificial coma to protect the brain during significant neurosurgery, are expected to bolster the market growth over the study period. Furthermore, the rising prevalence of neurological diseases globally is anticipated to boost the market growth over the forecast period. For instance, according to a study published in the Journal of Clinical Medicine in February 2023, neurological disorders currently affect around 15% of the global population. They are among the leading causes of physical and cognitive disabilities worldwide.
Furthermore, according to the American Cancer Society 2023 update, about 24,810 cases of new malignant tumors of the brain or spinal cord cases were diagnosed in 2023 in the United States. These numbers would be much higher if benign (non-cancer) tumors were also included. Therefore, the high estimated prevalence of neurological cancers is anticipated to increase the demand for artificial coma, bolstering the market growth.
Moreover, a rise in the adoption of artificial coma drugs in major brain surgeries may further contribute to market growth. For instance, according to an article published in PubMed in January 2022, propofol causes a specific reorganization of the brain's neural networks when a person loses consciousness. The brain network's response to propofol in individuals with consciousness problems may disclose the patient's underlying potential for consciousness.
Furthermore, the presence of key players and their strategic product launches are expected to bolster market growth. For instance, in August 2022, Genixus, a pharmaceutical company, launched propofol as a critical offering in its KinetiX platform, specifically in RTA syringe products. The KinetiX RTA platform debuted its propofol syringe, which was designed to optimize workflows and improve care delivery.
Thus, the high prevalence of brain-related diseases and the rise in the adoption of artificial coma procedures are expected to bolster market growth. However, the side effects, such as confusion, delirium, and immobility, associated with artificial coma may hinder the market growth over the forecast period.
Artificial Coma/Medically Induced Coma Market Trends
The Traumatic Brain Injury Segment is Expected to Witness a Positive Growth During the Forecast Period
Traumatic brain injuries (TBIs) include car and motorcycle accidents, sports injuries, abusive head trauma, gunshot wounds, and workplace injuries. The TBI segment is expected to witness significant growth in the studied market owing to the increase in the burden of TBIs across the globe and the rise in medically induced coma for TBI-related surgical procedures.
For instance, according to the study published in UpToDate Journal in May 2023, traumatic brain injury represents a significant challenge to global health and productivity, and the current global estimates indicate an annual incidence of TBI ranging from 27 to 69 million cases. Hence, with such a high number of people facing TBIs, there is a rise in demand for proper artificial coma proceedings for the patient to conduct significant surgeries on the brain.
Furthermore, increasing government initiatives to support TBI patients is expected to bolster the segment growth over the study period. For instance, in March 2023, the FY23 Defense Appropriations Act allocated funds to the Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP). This funding aims to bolster research efforts focused on enhancing the treatment, prevention, and early detection of traumatic brain injuries (TBIs) while also advancing psychological health.
Thus, owing to the increase in TBIs and the increase in government investment in TBI-related research and development, the studied segment is expected to witness significant growth over the forecast period.
North America is Expected to Witness a Significant Growth During the Forecast Period
North America is expected to witness significant market growth owing to better healthcare infrastructure and the presence of major industry players. Moreover, an increase in the prevalence of brain tumors is further expected to bolster market growth. For instance, as per the May 2022 update by the Canadian Cancer Society, 3,200 Canadians were diagnosed with brain and spinal cord cancer in Canada in 2022.
Furthermore, as per the May 2023 update by the Centers for Disease Control and Prevention, every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes. High occurrence of stroke leads to brain complications, which require complex surgeries, which thereby utilize the artificially induced coma proceedings and thus lead to market growth over the forecast period.
Furthermore, the presence of key players and their strategic product launches are expected to augment the market growth in North America. For instance, in April 2022, Avet Pharmaceuticals Inc. launched its AB-rated generic equivalent of DIPRIVAN (Propofol) Injectable Emulsion USP under Propofol Injectable Emulsion, USP 10 mg/mL. This launch comes in three sizes, i.e., 20, 50, and 100 ml single patient-use vials. The company launched these products after receiving FDA approval for its abbreviated new drug application.
Thus, due to increased brain-related diseases and the rise in strategic product launches, North America is expected to witness significant growth over the forecast period.
Artificial Coma/Medically Induced Coma Industry Overview
The artificial coma/medically induced coma market is semi-consolidated due to the presence of several companies operating globally and regionally. With strategic activities such as agreements and collaborations, the market players distribute the products to various countries globally. Some companies operating in the market include B Braun SE, Baxter Healthcare Corporation, Fresenius SE & Co. KGaA, and Aspen Holdings.
Artificial Coma/Medically Induced Coma Market Leaders
-
B Braun SE
-
Baxter Healthcare Corporation
-
Aspen Holdings
-
Fresenius SE & Co. KGaA
-
Piramal Enterprises Ltd.
*Disclaimer: Major Players sorted in no particular order
Artificial Coma/Medically Induced Coma Market News
- May 2024: Hikma Pharmaceuticals PLC, a pharmaceutical company, launched its Midazolam Injection, USP, in doses of 2 mg/2 mL and 10 mg/2 mL. This prefilled syringe product targets preoperative sedation, anxiolysis, and amnesia, with intramuscular or intravenous administration flexibility.
- May 2023: Genixus, a pharmaceutical company, partnered with the 340B Prime Vendor Program, overseen by Apexus LLC. This collaboration aims to supply hospitals with innovative KinetiX Propofol 1% ready-to-administer (RTA) syringes.
Artificial Coma/Medically Induced Coma Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 The Growing Burden of Various Brain Diseases and Injuries
4.2.2 Rise in Surgical Procedures
4.3 Market Restraints
4.3.1 Side Effects Associated with the Anesthesia Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Drug Type
5.1.1 Propofol
5.1.2 Barbiturate
5.1.3 Others
5.2 By Application
5.2.1 Status Epilepticus
5.2.2 Stroke
5.2.3 Traumatic Brain Injury
5.2.4 Brain Infections
5.2.5 Drug Overdose
5.2.6 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Drug Stores & Retail Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Rest of the World
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 B. Braun SE
6.1.2 Baxter Healthcare Corporation
6.1.3 Dr. Reddy's Laboratories
6.1.4 Fresenius SE & Co. KGaA
6.1.5 Hikma Pharmaceuticals
6.1.6 Pfizer Inc.
6.1.7 Piramal Enterprises Ltd
6.1.8 Aspen Holdings
6.1.9 Eisai Inc.
6.1.10 Flagship Biotech International Pvt Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Artificial Coma/Medically Induced Coma Industry Segmentation
As per the scope of the report, a controlled amount of an anesthetic agent, such as barbiturates like pentobarbital or thiopental, causes a transient coma known as an induced coma, sometimes referred to as a medically induced coma, barbiturate-induced coma, or drug-induced coma.
The artificial coma/medically induced coma market is segmented by drug type, application, distribution channel, and geography. By drug type, the market is segmented into propofol, barbiturate, and other drug types. By application, the market is segmented into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and other applications. By distribution channel, the market is segmented into hospital pharmacies, drug stores, and retail pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the world. The report offers the market sizes and forecasts in terms of value (USD) for all the abovementioned segments.
| By Drug Type | |
| Propofol | |
| Barbiturate | |
| Others |
| By Application | |
| Status Epilepticus | |
| Stroke | |
| Traumatic Brain Injury | |
| Brain Infections | |
| Drug Overdose | |
| Others |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Drug Stores & Retail Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of the World |
Artificial Coma/Medically Induced Coma Market Research FAQs
What is the current Artificial Coma/Medically Induced Coma Market size?
The Artificial Coma/Medically Induced Coma Market is projected to register a CAGR of 3% during the forecast period (2024-2029)
Who are the key players in Artificial Coma/Medically Induced Coma Market?
B Braun SE, Baxter Healthcare Corporation, Aspen Holdings, Fresenius SE & Co. KGaA and Piramal Enterprises Ltd. are the major companies operating in the Artificial Coma/Medically Induced Coma Market.
Which is the fastest growing region in Artificial Coma/Medically Induced Coma Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Artificial Coma/Medically Induced Coma Market?
In 2024, the North America accounts for the largest market share in Artificial Coma/Medically Induced Coma Market.
What years does this Artificial Coma/Medically Induced Coma Market cover?
The report covers the Artificial Coma/Medically Induced Coma Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Artificial Coma/Medically Induced Coma Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Artificial Coma/Medically Induced Coma Industry Report
Statistics for the 2024 Artificial Coma/Medically Induced Coma market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Artificial Coma/Medically Induced Coma analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Artificial Coma/Medically Induced Coma Market Report Snapshots
